This is a good point. Newly launched generic drugs go through a period of rapid price adjustment, where at first they are priced only a little bit below the bra

This is a good point. Newly launched generic drugs go through a period of rapid price adjustment, where at first they are priced only a little bit below the brand-name drug. Then as more generics become available (and keep in mind we're talking about physical products with expiration dates, inventory and distribution delays, etc.) the best wholesale price drops. In theory this is an area where PBMs can add a lot of value, because they have broader visibility into the pricing of these drugs (both by researching manuf pricing and negotiating prices with pharmacies).